| Patient | Franklin D. Roosevelt |
|---|---|
| Date of birth | 1964-01-30 |
| Identifiers | MRN HR-ET002-SYN; SSN (made up) 000-02-5130 |
| Document date | 2026-03-27 |
| Author | Nathaniel Brooks, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Primary care visit for breathlessness, orthopnea, and leg swelling [S]
This fictional modern episode addresses the presenting concerns below. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
2 later historical claims are omitted because they describe events after the index age. See the teaching note.
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| August 25, 1921 | Paralytic illness in August 1921, diagnosed at the time as infantile paralysis (polio); paraplegic thereafter, with leg braces from early 1922 | D (CLM-0003) |
| Proposed in 2003 about the 1921 illness | Guillain-Barré syndrome proposed retrospectively as the cause of the 1921 paralysis; disputed | R (CLM-0004) |
| May 1941 | Severe iron deficiency anemia in May 1941, hemoglobin reported at 4.5 g/100 mL | D (CLM-0005) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| father | Died in 1900; cause not recorded in the cited source | D (CLM-0009) | |
| mother | Died in September 1941; cause not recorded in the cited source | D (CLM-0009) |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Sacubitril 24 mg / valsartan 26 mg oral tablet, one tablet by mouth twice daily | One tablet by mouth twice daily | Oral route | 2026-03-27 to 2026-04-10 | completed | S |
| Carvedilol 3.125 mg oral tablet, one tablet by mouth twice daily with food | One tablet by mouth twice daily with food | Oral route | 2026-03-27 to 2026-04-10 | completed | S |
| Empagliflozin 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-03-27 | active | S |
| Furosemide 20 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-03-27 to 2026-06-26 | completed | S |
| Atorvastatin 40 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-03-27 | active | S |
| Nicotine 21 mg/24 hr transdermal patch, apply one patch daily | Apply one patch to the skin daily | Topical route | 2026-03-27 to 2026-06-26 | completed | S |
Positive for the concerns in the history of present illness. Alert, fully oriented, and good-humored; tends to minimize symptoms. Mood euthymic; PHQ-2 negative. No other systems reported as affected in this synthetic episode. [S]
Alert and engaged. Uses a manual wheelchair since a paralytic illness at age 39; independent in transfers and upper-body activities of daily living. Breathless after propelling the wheelchair short distances and when lying flat; NYHA class III at intake. [S]
Vital signs recorded on 2026-03-27; see the Vital Signs section. Mental status: Alert, fully oriented, and good-humored; tends to minimize symptoms; Mood euthymic; PHQ-2 negative. The physical examination is limited to the findings relevant to this synthetic episode. [S]
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-27 | Body height | 188 | cm | S |
| 2026-03-27 | Body weight | 88 | kg | S |
| 2026-03-27 | Body mass index (BMI) [Ratio] | 24.9 | kg/m2 | S |
| 2026-03-27 | Systolic blood pressure | 186 | mm[Hg] | S |
| 2026-03-27 | Diastolic blood pressure | 108 | mm[Hg] | S |
| 2026-03-27 | Heart rate | 96 | /min | S |
| 2026-03-27 | Respiratory rate | 22 | /min | S |
| 2026-03-27 | Body temperature | 36.9 | Cel | S |
| 2026-03-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 93 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-27 | Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma | 2850 | pg/mL | <=125 pg/mL | High | S |
| 2026-03-27 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-03-27 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-27 | Creatinine [Mass/volume] in Serum or Plasma | 1.18 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-03-27 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 70 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-03-27 | Glucose [Mass/volume] in Serum or Plasma | 104 | mg/dL | 70-99 mg/dL | High | S |
| 2026-03-27 | Hemoglobin [Mass/volume] in Blood | 12.6 | g/dL | 13.2-16.6 g/dL | Low | S |
| 2026-03-27 | Ferritin [Mass/volume] in Serum or Plasma | 48 | ng/mL | 30-400 ng/mL | Normal | S |
| 2026-03-27 | Iron saturation [Mass Fraction] in Serum or Plasma | 16 | % | 20-50% | Low | S |
| 2026-03-27 | Thyrotropin [Units/volume] in Serum or Plasma | 2.1 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 2026-03-27 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 132 | mg/dL | <=99 mg/dL | High | S |
| 2026-03-27 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.9 | % | <=5.6% | High | S |
| 2026-03-27 | Albumin/Creatinine [Mass Ratio] in Urine | 64 | mg/g | <=30 mg/g | High | S |
| 2026-03-27 | Overall summary score [KCCQ-12] | 38 | {score} | S | ||
| 2026-03-27 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Hypertensive heart disease with heart failure; synthetic modern diagnosis linked to the documented 1944 findings | active | confirmed | I11.0 | S — Synthetic active diagnosis for the teaching episode; the 1944 findings remain D. |
| Heart failure with reduced ejection fraction, NYHA class III at diagnosis | active | confirmed | I50.22 | S — Synthetic diagnosis confirmed by echocardiogram in the modern episode. |
| Nicotine dependence, cigarettes | active | confirmed | F17.210 | S — Synthetic modern diagnosis linked to documented cigarette smoking. |
| Iron deficiency anemia in heart failure, repleted with intravenous iron | resolved | confirmed | D50.9 | S — Synthetic finding that echoes the documented 1941 anemia; the modern values are S. |
| Paraplegia from a paralytic illness at age 39, historically diagnosed as poliomyelitis; cause retrospectively disputed | active | provisional | B91 | S — Synthetic modern coding of the documented diagnosis; the alternative cause remains R. |
| Prediabetes | active | confirmed | R73.03 | S — Synthetic finding from the baseline HbA1c. |
| Hyperlipidemia | active | confirmed | E78.5 | S — Synthetic finding from the baseline LDL cholesterol. |